WO2021170117A1 - 一种识别afp抗原短肽的t细胞受体及其编码序列 - Google Patents
一种识别afp抗原短肽的t细胞受体及其编码序列 Download PDFInfo
- Publication number
- WO2021170117A1 WO2021170117A1 PCT/CN2021/078277 CN2021078277W WO2021170117A1 WO 2021170117 A1 WO2021170117 A1 WO 2021170117A1 CN 2021078277 W CN2021078277 W CN 2021078277W WO 2021170117 A1 WO2021170117 A1 WO 2021170117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tcr
- chain
- amino acid
- seq
- exon
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 294
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 286
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 56
- 108091007433 antigens Proteins 0.000 title abstract description 40
- 102000036639 antigens Human genes 0.000 title abstract description 40
- 239000000427 antigen Substances 0.000 title abstract description 39
- 210000004027 cell Anatomy 0.000 claims abstract description 91
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 47
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 42
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 42
- 239000013598 vector Substances 0.000 claims abstract description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 81
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 53
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims description 50
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims description 50
- 239000002773 nucleotide Substances 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 50
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims description 49
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims description 49
- 235000001014 amino acid Nutrition 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 42
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 239000000833 heterodimer Substances 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 101150008942 J gene Proteins 0.000 claims description 6
- 230000002998 immunogenetic effect Effects 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 abstract description 35
- 230000027455 binding Effects 0.000 abstract description 6
- 230000002463 transducing effect Effects 0.000 abstract description 5
- 208000030062 persistent idiopathic facial pain Diseases 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 13
- 210000003000 inclusion body Anatomy 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 230000009258 tissue cross reactivity Effects 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000004153 renaturation Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 101710130607 Valacyclovir hydrolase Proteins 0.000 description 2
- 102100025139 Valacyclovir hydrolase Human genes 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 2
- 229940099500 cystamine Drugs 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100172874 Caenorhabditis elegans sec-3 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000703392 Tribec virus Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464481—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to TCRs capable of recognizing short peptides derived from AFP antigens and their coding sequences.
- the present invention also relates to AFP-specific T cells obtained by transducing the above-mentioned TCRs, and their use in the prevention and treatment of AFP-related diseases.
- AFP ( ⁇ Fetoprotein), also known as ⁇ fetoprotein, is a protein expressed during embryonic development and the main component of embryonic serum. During development, AFP has a relatively high level of expression in the yolk sac and liver, and is subsequently inhibited. In hepatocellular carcinoma, the expression of AFP is activated (Butterfield et al. J Immunol., 2001, Apr 15; 166(8): 5300-8). After AFP is produced in the cell, it is degraded into small molecule polypeptides, and combined with MHC (major histocompatibility complex) molecules to form a complex, which is presented to the cell surface.
- TSSELMAITR (SEQ ID NO: 9) is a short peptide derived from AFP antigen and a target for the treatment of AFP-related diseases.
- T cell adoptive immunotherapy is the transfer of reactive T cells that are specific to target cell antigens into the patient's body to make them work against the target cells.
- T cell receptor TCR
- T cell receptor is a membrane protein on the surface of T cells that can recognize short antigenic peptides on the surface of corresponding target cells.
- pMHC complex antigen-presenting cells
- those skilled in the art are dedicated to isolating the TCR specific to the AFP antigen short peptide, and transducing the TCR to T cells to obtain T cells specific to the AFP antigen short peptide, so that they can be used in cellular immunotherapy. Play a role.
- the purpose of the present invention is to provide a T cell receptor that recognizes short peptides of AFP antigen.
- the first aspect of the present invention provides a T cell receptor (TCR), which can bind to the TSSELMAITR-HLA A1101 complex.
- TCR T cell receptor
- the TCR comprises a TCR ⁇ chain variable domain and a TCR ⁇ chain variable domain
- the amino acid sequence of CDR3 of the TCR ⁇ chain variable domain is AVVATDSWGKLQ (SEQ ID NO: 12); and/or the The amino acid sequence of CDR3 of the TCR ⁇ chain variable domain is ASSLVAGARTDTQY (SEQ ID NO: 15).
- the three complementarity determining regions (CDRs) of the TCR ⁇ chain variable domain are:
- the three complementarity determining regions of the variable domain of the TCR ⁇ chain are:
- the TCR comprises a TCR ⁇ chain variable domain and a TCR ⁇ chain variable domain
- the TCR ⁇ chain variable domain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO:1; and/ Or the TCR ⁇ chain variable domain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 5.
- the TCR comprises an alpha chain variable domain amino acid sequence SEQ ID NO:1.
- the TCR comprises the ⁇ -chain variable domain amino acid sequence SEQ ID NO: 5.
- the TCR is an ⁇ heterodimer, which comprises a TCR ⁇ chain constant region TRAC*01 and a TCR ⁇ chain constant region TRBC1*01 or TRBC2*01.
- the alpha chain amino acid sequence of the TCR is SEQ ID NO: 3 and/or the beta chain amino acid sequence of the TCR is SEQ ID NO: 7.
- the TCR is soluble.
- the TCR is single-stranded.
- the TCR is formed by linking the ⁇ chain variable domain and the ⁇ chain variable domain through a peptide linking sequence.
- the TCR is at the 11th, 13th, 19th, 21st, 53, 76, 89, 91, or 94th amino acid positions of the ⁇ chain variable region, and/or the reciprocal of the ⁇ chain J gene short peptide amino acid There are one or more mutations in position 3, position 5, or position 7; and/or the TCR has amino acids 11, 13, 19, 21, 53, 76, 89, 91 in the ⁇ chain variable region , Or position 94, and/or ⁇ -chain J gene short peptide amino acid in the penultimate position 2, the last 4 position or the last 6 position has one or more mutations, wherein the amino acid position number is according to IMGT (International Immunogenetics Information) The position number listed in the system).
- IMGT International Immunogenetics Information
- the amino acid sequence of the ⁇ chain variable domain of the TCR comprises SEQ ID NO: 32 and/or the amino acid sequence of the ⁇ chain variable domain of the TCR comprises SEQ ID NO: 34.
- amino acid sequence of the TCR is SEQ ID NO: 30.
- the TCR includes (a) all or part of the TCR ⁇ chain except the transmembrane domain; and (b) all or part of the TCR ⁇ chain except the transmembrane domain;
- (a) and (b) each comprise a functional variable domain, or comprise a functional variable domain and at least a part of the constant domain of the TCR chain.
- cysteine residues form an artificial disulfide bond between the ⁇ and ⁇ chain constant domains of the TCR.
- cysteine residues forming artificial disulfide bonds in the TCR are substituted for one or more sets of sites selected from the following:
- the alpha chain amino acid sequence of the TCR is SEQ ID NO: 26 and/or the beta chain amino acid sequence of the TCR is SEQ ID NO: 28.
- the alpha chain variable region and the beta chain constant region of the TCR contain artificial interchain disulfide bonds.
- cysteine residues forming the artificial interchain disulfide bond in the TCR are substituted for one or more sets of sites selected from the following:
- the TCR comprises an ⁇ chain variable domain and a ⁇ chain variable domain, and all or part of the ⁇ chain constant domain except the transmembrane domain, but it does not comprise the ⁇ chain constant domain.
- the TCR The ⁇ chain variable domain and ⁇ chain form a heterodimer.
- a conjugate is bound to the C- or N-terminus of the ⁇ chain and/or ⁇ chain of the TCR.
- the conjugate that binds to the T cell receptor is a detectable marker, a therapeutic agent, a PK modified portion, or a combination of any of these substances.
- the therapeutic agent is an anti-CD3 antibody.
- the second aspect of the present invention provides a multivalent TCR complex comprising at least two TCR molecules, and at least one of the TCR molecules is the TCR described in the first aspect of the present invention.
- the third aspect of the present invention provides a nucleic acid molecule, the nucleic acid molecule comprising a nucleic acid sequence encoding the TCR molecule of the first aspect of the present invention or its complementary sequence.
- the nucleic acid molecule comprises the nucleotide sequence SEQ ID NO: 2 or SEQ ID NO: 33 encoding the variable domain of the TCR ⁇ chain.
- the nucleic acid molecule comprises the nucleotide sequence SEQ ID NO: 6 or SEQ ID NO: 35 encoding the variable domain of the TCR ⁇ chain.
- the nucleic acid molecule comprises a nucleotide sequence of SEQ ID NO: 4 encoding a TCR ⁇ chain and/or a nucleotide sequence of SEQ ID NO: 8 encoding a TCR ⁇ chain.
- the fourth aspect of the present invention provides a vector containing the nucleic acid molecule described in the third aspect of the present invention; preferably, the vector is a viral vector; more preferably, the vector is a slow Viral vector.
- the fifth aspect of the present invention provides an isolated host cell containing the vector according to the fourth aspect of the present invention or the nucleic acid molecule according to the third aspect of the present invention integrated into the genome .
- the sixth aspect of the present invention provides a cell that transduces the nucleic acid molecule of the third aspect of the present invention or the vector of the fourth aspect of the present invention; preferably, the cell is a T cell or a stem cell .
- the seventh aspect of the present invention provides a pharmaceutical composition containing a pharmaceutically acceptable carrier and the TCR described in the first aspect of the present invention, the TCR complex described in the second aspect of the present invention, and the The nucleic acid molecule according to the third aspect of the invention, the vector according to the fourth aspect of the invention, or the cell according to the sixth aspect of the invention.
- the eighth aspect of the present invention provides the T cell receptor according to the first aspect of the present invention, or the TCR complex according to the second aspect of the present invention, the nucleic acid molecule according to the third aspect of the present invention, and the fourth aspect of the present invention.
- the use of the vector described in this aspect or the cell described in the sixth aspect of the present invention is used to prepare a medicine for treating tumors or autoimmune diseases, preferably the tumor is liver cancer.
- the eighth aspect of the present invention provides the T cell receptor according to the first aspect of the present invention, or the TCR complex according to the second aspect of the present invention, the nucleic acid molecule according to the third aspect of the present invention, and the fourth aspect of the present invention.
- the vector described in this aspect or the cell described in the sixth aspect of the present invention is used to prepare drugs for treating tumors or autoimmune diseases.
- the tumor is liver cancer.
- the ninth aspect of the present invention provides a method for treating diseases, comprising administering an appropriate amount of the T cell receptor according to the first aspect of the present invention or the TCR complex according to the second aspect of the present invention to a subject in need of treatment ,
- the nucleic acid molecule according to the third aspect of the present invention, the vector according to the fourth aspect of the present invention, or the cell according to the sixth aspect of the present invention, or the pharmaceutical composition according to the seventh aspect of the present invention preferably, the The disease is a tumor, preferably the tumor is liver cancer.
- Figure 1a, Figure 1b, Figure 1c, Figure 1d, Figure 1e and Figure 1f are the TCR ⁇ chain variable domain amino acid sequence, TCR ⁇ chain variable domain nucleotide sequence, TCR ⁇ chain amino acid sequence, TCR ⁇ chain nucleotide sequence, The amino acid sequence of the TCR ⁇ chain of the leader sequence and the nucleotide sequence of the TCR ⁇ chain with the leader sequence.
- Figure 2a, Figure 2b, Figure 2c, Figure 2d, Figure 2e and Figure 2f are the TCR ⁇ chain variable domain amino acid sequence, TCR ⁇ chain variable domain nucleotide sequence, TCR ⁇ chain amino acid sequence, TCR ⁇ chain nucleotide sequence, The amino acid sequence of the TCR ⁇ chain of the leader sequence and the nucleotide sequence of the TCR ⁇ chain with the leader sequence.
- Figure 3 shows the CD8 + and tetramer-PE double positive staining results of monoclonal cells.
- Figures 4a and 4b show the amino acid sequence and nucleotide sequence of the soluble TCR ⁇ chain, respectively.
- Figures 5a and 5b show the amino acid sequence and nucleotide sequence of the soluble TCR ⁇ chain, respectively.
- Figures 6a and 6b are gel images of soluble TCR obtained after purification. Among them, the left lanes of Fig. 6a and Fig. 6b are non-reducing glue and reducing glue, respectively, and the right lanes are all molecular weight markers.
- Figures 7a and 7b are the amino acid sequence and nucleotide sequence of the single-stranded TCR, respectively.
- Figures 8a and 8b are the amino acid sequence and nucleotide sequence of the variable domain of the single-chain TCR ⁇ chain, respectively.
- Figures 9a and 9b are the amino acid sequence and nucleotide sequence of the variable domain of the single-stranded TCR ⁇ chain, respectively.
- Figures 10a and 10b are the amino acid sequence and nucleotide sequence of the single-stranded TCR linker, respectively.
- Figure 11 is a gel image of a soluble single-chain TCR obtained after purification.
- the leftmost lane is non-reducing glue
- the middle lane is molecular weight marker
- the rightmost lane is reducing glue.
- Figure 12 is a BIAcore kinetic map of the combination of soluble TCR and TSSELMAITR-HLA A1101 complex of the present invention.
- Figure 13 is a BIAcore kinetic map of the combination of soluble single-chain TCR and TSSELMAITR-HLA A1101 complex of the present invention.
- Figure 14 shows the result of the ELISPOT activation function verification of the obtained T cell clone.
- Figure 15 shows the results of the ELISPOT activation function verification of the effector cells transduced with the TCR of the present invention.
- the present invention also provides a nucleic acid molecule encoding the TCR and a vector containing the nucleic acid molecule. In addition, the present invention also provides cells transducing the TCR of the present invention.
- MHC molecules are proteins of the immunoglobulin superfamily, and can be class I or class II MHC molecules. Therefore, it is specific for the presentation of antigens. Different individuals have different MHCs and can present different short peptides in a protein antigen to the surface of their respective APC cells. Human MHC is usually called HLA gene or HLA complex.
- T cell receptor is the only receptor for specific antigen peptides presented on the main histocompatibility complex (MHC).
- MHC main histocompatibility complex
- APC antigen presenting cells
- T cells with different antigen specificities exerted immune effects on their target cells.
- TCR is a glycoprotein on the surface of the cell membrane that exists as a heterodimer of ⁇ chain/ ⁇ chain or ⁇ chain/ ⁇ chain.
- TCR heterodimers are composed of ⁇ and ⁇ chains, while 5% of T cells have TCRs composed of ⁇ and ⁇ chains.
- the natural ⁇ heterodimeric TCR has an ⁇ chain and a ⁇ chain, and the ⁇ chain and the ⁇ chain constitute subunits of the ⁇ heterodimeric TCR.
- each chain of ⁇ and ⁇ includes a variable region, a connecting region and a constant region.
- the ⁇ chain usually also contains a short variable region between the variable region and the connecting region, but the variable region is often regarded as the connecting region.
- Each variable region contains 3 CDRs (complementarity determining regions), CDR1, CDR2 and CDR3, which are embedded in framework regions.
- the CDR region determines the combination of TCR and pMHC complex, where CDR3 is recombined from the variable region and the connecting region, which is called the hypervariable region.
- the ⁇ and ⁇ chains of TCR are generally regarded as having two "domains" each, namely a variable domain and a constant domain.
- the variable domain is composed of a connected variable region and a connecting region.
- the sequence of the constant domain of TCR can be found in the public database of the International Immunogenetics Information System (IMGT).
- IMGT International Immunogenetics Information System
- the sequence of the constant domain of the ⁇ chain of the TCR molecule is "TRAC*01”
- the sequence of the constant domain of the ⁇ chain of the TCR molecule is "TRBC1*" 01" or "TRBC2*01”.
- the ⁇ and ⁇ chains of TCR also contain transmembrane and cytoplasmic regions, which are very short.
- polypeptide of the present invention TCR of the present invention
- T cell receptor of the present invention T cell receptor of the present invention
- the position numbers of the amino acid sequence of TRAC*01 and TRBC1*01 or TRBC2*01 in the present invention are numbered in sequence from the N-terminus to the C-terminus, such as TRBC1*01 or TRBC2*01
- the 60th amino acid is P (proline)
- Pro60 of TRBC1*01 or TRBC2*01 exon 1 in the present invention or It is expressed as the 60th amino acid of TRBC1*01 or TRBC2*01 exon 1.
- the 61st amino acid is Q(glutamine) in sequence from N-terminal to C-terminal.
- Amide in the present invention, it can be described as Gln61 of TRBC1*01 or TRBC2*01 exon 1, or it can be expressed as the 61st amino acid of TRBC1*01 or TRBC2*01 exon 1, and other And so on.
- the position numbers of the amino acid sequences of TRAV and TRBV in the variable regions follow the position numbers listed in IMGT.
- the position number listed in IMGT is 46, it is described as the 46th amino acid of TRAV in the present invention, and the rest can be deduced by analogy.
- sequence position numbers of other amino acids have special instructions, follow the special instructions.
- the antigen In the process of antigen processing, the antigen is degraded inside the cell and then carried to the cell surface by MHC molecules. T cell receptors can recognize peptide-MHC complexes on the surface of antigen-presenting cells. Therefore, the first aspect of the present invention provides a TCR molecule capable of binding to the TSSELMAITR-HLA A1101 complex. Preferably, the TCR molecule is isolated or purified. The ⁇ and ⁇ chains of the TCR each have three complementarity determining regions (CDR).
- CDR complementarity determining regions
- the ⁇ chain of the TCR includes a CDR having the following amino acid sequence:
- the three complementarity determining regions of the variable domain of the TCR ⁇ chain are:
- the TCR molecule of the present invention refers to a TCR molecule comprising the aforementioned ⁇ and/or ⁇ chain CDR region sequence and any suitable framework structure.
- the TCR ⁇ chain variable domain of the present invention is an amino acid sequence that has at least 90%, preferably 95%, and more preferably 98% sequence identity with SEQ ID NO:1; and/or the TCR ⁇ chain variable domain of the present invention is the same as SEQ ID NO: 5 has an amino acid sequence with at least 90%, preferably 95%, more preferably 98% sequence identity.
- the TCR molecule of the present invention is a heterodimer composed of ⁇ and ⁇ chains.
- the ⁇ chain of the heterodimeric TCR molecule includes a variable domain and a constant domain, and the amino acid sequence of the ⁇ chain variable domain includes the CDR1 (SEQ ID NO: 10) and CDR2 (SEQ ID NO: 10) of the above ⁇ chain. ID NO: 11) and CDR3 (SEQ ID NO: 12).
- the TCR molecule comprises an alpha chain variable domain amino acid sequence SEQ ID NO:1. More preferably, the alpha chain variable domain amino acid sequence of the TCR molecule is SEQ ID NO:1.
- the ⁇ chain of the heterodimeric TCR molecule includes a variable domain and a constant domain
- the amino acid sequence of the ⁇ chain variable domain includes CDR1 (SEQ ID NO: 13) and CDR2 (SEQ ID NO: 13) of the above ⁇ chain. NO: 14) and CDR3 (SEQ ID NO: 15).
- the TCR molecule comprises the ⁇ -chain variable domain amino acid sequence SEQ ID NO: 5. More preferably, the amino acid sequence of the ⁇ chain variable domain of the TCR molecule is SEQ ID NO: 5.
- the TCR molecule of the present invention is a single-stranded TCR molecule composed of part or all of the alpha chain and/or part or all of the beta chain.
- single-chain TCR molecules please refer to Chung et al (1994) Proc. Natl. Acad. Sci. USA 91, 12654-12658. According to the literature, those skilled in the art can easily construct single-chain TCR molecules containing the CDRs of the present invention.
- the single-stranded TCR molecule includes V ⁇ , V ⁇ , and C ⁇ , and is preferably connected in order from N-terminal to C-terminal.
- the alpha chain variable domain amino acid sequence of the single-chain TCR molecule includes CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 11) and CDR3 (SEQ ID NO: 12) of the aforementioned ⁇ chain.
- the single-chain TCR molecule comprises an ⁇ -chain variable domain amino acid sequence SEQ ID NO:1. More preferably, the alpha chain variable domain amino acid sequence of the single-chain TCR molecule is SEQ ID NO:1.
- the ⁇ -chain variable domain amino acid sequence of the single-chain TCR molecule includes CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO: 14) and CDR3 (SEQ ID NO: 15) of the ⁇ -chain.
- the single-chain TCR molecule comprises the ⁇ -chain variable domain amino acid sequence SEQ ID NO: 5. More preferably, the ⁇ -chain variable domain amino acid sequence of the single-chain TCR molecule is SEQ ID NO: 5.
- the constant domain of the TCR molecule of the present invention is a human constant domain.
- the constant domain sequence of the alpha chain of the TCR molecule of the present invention can be "TRAC*01”
- the constant domain sequence of the beta chain of the TCR molecule can be "TRBC1*01” or "TRBC2*01”.
- the 53rd position of the amino acid sequence given in IMGT's TRAC*01 is Arg, which is represented here as: Arg53 of TRAC*01 exon 1, and so on.
- the amino acid sequence of the alpha chain of the TCR molecule of the present invention is SEQ ID NO: 3, and/or the amino acid sequence of the beta chain is SEQ ID NO: 7.
- TCR The naturally occurring TCR is a membrane protein that is stabilized by its transmembrane domain. Like immunoglobulins (antibodies) as antigen recognition molecules, TCR can also be developed for diagnosis and treatment, and soluble TCR molecules need to be obtained. Soluble TCR molecules do not include their transmembrane regions. Soluble TCR has a wide range of uses. It can be used not only to study the interaction between TCR and pMHC, but also as a diagnostic tool for detecting infections or as a marker for autoimmune diseases. Similarly, soluble TCR can be used to deliver therapeutic agents (such as cytotoxic compounds or immunostimulatory compounds) to cells presenting specific antigens. In addition, soluble TCR can also be combined with other molecules (such as anti-CD3 antibodies). To redirect T cells to target cells that present specific antigens. The present invention also obtains the soluble TCR specific to the AFP antigen short peptide.
- the TCR of the present invention may be a TCR with artificial disulfide bonds introduced between the residues of the constant domains of its ⁇ and ⁇ chains.
- Cysteine residues form artificial interchain disulfide bonds between the alpha and beta chain constant domains of the TCR.
- Cysteine residues can be substituted for other amino acid residues at appropriate positions in the natural TCR to form artificial interchain disulfide bonds. For example, replacing Thr48 of TRAC*01 exon 1 and replacing the cysteine residue of Ser57 of TRBC1*01 or TRBC2*01 exon 1 to form a disulfide bond.
- Other sites for introducing cysteine residues to form disulfide bonds can also be: Thr45 of TRAC*01 exon 1 and TRBC1*01 or Ser77 of TRBC2*01 exon 1; TRAC*01 exon Tyr10 of 1 and Ser17 of TRBC1*01 or TRBC2*01 exon 1; Thr45 of TRAC*01 exon 1 and Asp59 of TRBC1*01 or TRBC2*01 exon 1; TRAC*01 exon 1 Ser15 and Glu15 of TRBC1*01 or TRBC2*01 exon 1; Arg53 of TRAC*01 exon 1 and Ser54 of TRBC1*01 or TRBC2*01 exon 1; Pro89 and Pro89 of TRAC*01 exon 1 Ala19 of TRBC1*01 or TRBC2*01 exon 1; or Tyr10 of TRAC*01 exon 1 and Glu20 of TRBC1*01 or TRBC2*01 exon 1.
- cysteine residues replace any set of positions in the constant domains of the ⁇ and ⁇ chains.
- a maximum of 50, or a maximum of 30, or a maximum of 15, or a maximum of 10, or a maximum of 8 or less amino acids can be truncated at one or more C-termini of the TCR constant domain of the present invention, so that it does not include Cysteine residues can be used to delete natural disulfide bonds, and the cysteine residues that form natural disulfide bonds can also be mutated to another amino acid to achieve the above purpose.
- the TCR of the present invention may contain artificial disulfide bonds introduced between the residues of the constant domains of its ⁇ and ⁇ chains. It should be noted that, with or without the introduced artificial disulfide bonds between the constant domains, the TCR of the present invention can contain the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence.
- the TRAC constant domain sequence of TCR and the TRBC1 or TRBC2 constant domain sequence can be connected by natural disulfide bonds present in the TCR.
- the TCR of the present invention also includes a TCR that has mutations in its hydrophobic core region.
- These mutations in the hydrophobic core region are preferably mutations that can improve the stability of the soluble TCR of the present invention, as described in Publication No. It is described in the patent document of WO2014/206304.
- Such a TCR can be mutated at the following variable domain hydrophobic core positions: ( ⁇ and/or ⁇ chain) variable region amino acid positions 11, 13, 19, 21, 53, 76, 89, 91, 94, and/ Or alpha chain J gene (TRAJ) short peptide amino acid position is the 3rd, 5th and 7th position from the bottom, and/or ⁇ chain J gene (TRBJ) short peptide amino acid position is the 2nd, 4th and 6th position from the bottom, the position number of the amino acid sequence According to the position number listed in the International Immunogenetics Information System (IMGT).
- IMGT International Immunogenetics Information System
- the TCR in which the hydrophobic core region is mutated may be a stable soluble single-chain TCR composed of a flexible peptide chain connecting the variable domains of the ⁇ and ⁇ chains of the TCR.
- the flexible peptide chain in the present invention can be any peptide chain suitable for connecting the variable domains of the TCR ⁇ and ⁇ chains.
- the ⁇ -chain variable domain amino acid sequence is SEQ ID NO: 32
- the encoded nucleotide sequence is SEQ ID NO: 33
- ⁇ -chain variable domain amino acid sequence It is SEQ ID NO: 34
- the encoded nucleotide sequence is SEQ ID NO: 35.
- Patent Document 201680003540.2 also discloses that the introduction of artificial interchain disulfide bonds between the ⁇ chain variable region and the ⁇ chain constant region of the TCR can significantly improve the stability of the TCR. Therefore, the high-affinity TCR of the present invention may also contain artificial interchain disulfide bonds between the ⁇ chain variable region and the ⁇ chain constant region.
- cysteine residue that forms an artificial interchain disulfide bond between the ⁇ chain variable region and the ⁇ chain constant region of the TCR is substituted: the 46th amino acid of TRAV and TRBC1*01 or TRBC2* The 60th amino acid of 01 exon 1; the 47th amino acid of TRAV and the 61st amino acid of TRBC1*01 or TRBC2*01 exon 1; the 46th amino acid of TRAV and the TRBC1*01 or TRBC2*01 exon The 61st amino acid of sub 1; or the 47th amino acid of TRAV and the 60th amino acid of TRBC1*01 or TRBC2*01 exon 1.
- such a TCR may comprise (i) all or part of the TCR ⁇ chain excluding its transmembrane domain, and (ii) all or part of the TCR ⁇ chain excluding its transmembrane domain, wherein (i) and (ii) ) Contains the variable domain and at least a part of the constant domain of the TCR chain, and the ⁇ chain and the ⁇ chain form a heterodimer. More preferably, such a TCR may include an ⁇ chain variable domain and a ⁇ chain variable domain and all or part of the ⁇ chain constant domain except the transmembrane domain, but it does not include the ⁇ chain constant domain. The chain variable domain and the ⁇ chain form a heterodimer.
- the TCR of the present invention can also be provided in the form of a multivalent complex.
- the multivalent TCR complex of the present invention comprises a polymer formed by combining two, three, four or more TCRs of the present invention.
- the tetramerization domain of p53 can be used to generate a tetramer, or more A complex formed by combining the TCR of the present invention with another molecule.
- the TCR complex of the present invention can be used to track or target cells presenting a specific antigen in vitro or in vivo, and can also be used to produce intermediates of other multivalent TCR complexes with such applications.
- the TCR of the present invention can be used alone or combined with the conjugate in a covalent or other manner, preferably in a covalent manner.
- the conjugate includes a detectable marker (for diagnostic purposes, the TCR is used to detect the presence of cells presenting the TSSELMAITR-HLA A1101 complex), a therapeutic agent, a PK (protein kinase) modified portion or any of the above substances The combination of binding or coupling.
- Detectable markers used for diagnostic purposes include, but are not limited to: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (electronic computed tomography technology) contrast agents, or capable of producing detectable products Of enzymes.
- Therapeutic agents that can be combined or coupled with the TCR of the present invention include but are not limited to: 1. Radionuclides (Koppe et al., 2005, Cancer metastasis reviews 24, 539); 2. Biotoxicity (Chaudhary et al., 1989) , Nature 339, 394; Epel et al., 2002, Cancer Immunology and Immunotherapy (Cancer Immunology and Immunotherapy 51, 565); 3. Cytokines such as IL-2, etc.
- Gold Nanoparticles/Nano Stick (Lapotko et al., 2005, Cancer letters 239, 36; Huang et al., 2006, Journal of the American Chemical Society 128, 2115); 7. Virus particles (Peng et al., 2004, Gene Treatment (Genetherapy) 11, 1234); 8. Liposomes (Mamot et al., 2005, Cancer research (Cancer research) 65, 11631); 9. Nano magnetic particles; 10. Prodrug activating enzymes (for example, DT-cardiac Diazyme (DTD) or biphenyl hydrolase-like protein (BPHL)); 11. Chemotherapeutics (for example, cisplatin) or any form of nanoparticles, etc.
- DTD DT-cardiac Diazyme
- BPHL biphenyl hydrolase-like protein
- the TCR of the present invention may also be a hybrid TCR containing sequences derived from more than one species.
- the TCR of the present invention may include a human variable domain and a murine constant domain. The disadvantage of this method is that it may trigger an immune response. Therefore, when it is used in adoptive T cell therapy, there should be a regulatory scheme for immunosuppression to allow the implantation of T cells expressing murine.
- the second aspect of the present invention provides a nucleic acid molecule encoding the TCR molecule of the first aspect of the present invention or a part thereof, which may be one or more CDRs, variable domains of ⁇ and/or ⁇ chains, and ⁇ chains and/ Or beta chain.
- nucleotide sequence encoding the ⁇ chain CDR region of the TCR molecule of the first aspect of the present invention is as follows:
- nucleotide sequence encoding the ⁇ chain CDR region of the TCR molecule of the first aspect of the present invention is as follows:
- the nucleotide sequence of the nucleic acid molecule of the present invention encoding the TCR ⁇ chain of the present invention includes SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, and/or the nucleotide sequence of the nucleic acid molecule of the present invention encoding the TCR ⁇ chain of the present invention.
- the nucleotide sequence includes SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21.
- the nucleotide sequence of the nucleic acid molecule of the present invention may be single-stranded or double-stranded, the nucleic acid molecule may be RNA or DNA, and may or may not contain introns.
- the nucleotide sequence of the nucleic acid molecule of the present invention does not contain introns but can encode the polypeptide of the present invention.
- the nucleotide sequence of the nucleic acid molecule of the present invention encoding the variable domain of the TCR ⁇ chain of the present invention includes SEQ ID NO: 2 and / Or the nucleotide sequence of the nucleic acid molecule of the present invention encoding the variable domain of the TCR ⁇ chain of the present invention includes SEQ ID NO: 6.
- the nucleotide sequence of the nucleic acid molecule of the present invention encoding the TCR ⁇ chain variable domain of the present invention includes SEQ ID NO: 33 and/or the nucleotide sequence of the nucleic acid molecule of the present invention encoding the TCR ⁇ chain variable domain of the present invention includes SEQ ID NO: 35. More preferably, the nucleotide sequence of the nucleic acid molecule of the present invention includes SEQ ID NO: 4 and/or SEQ ID NO: 8; or, the nucleotide sequence of the nucleic acid molecule of the present invention is SEQ ID NO: 31.
- nucleic acid sequence encoding the TCR of the present invention may be the same as the nucleic acid sequence shown in the drawings of the present invention or a degenerate variant.
- a "degenerate variant” refers to a nucleic acid sequence that encodes a protein sequence of SEQ ID NO: 1, but differs from the sequence of SEQ ID NO: 2.
- the nucleotide sequence can be codon optimized. Different cells use specific codons differently. According to the cell type, the codons in the sequence can be changed to increase the amount of expression. Codon usage tables for mammalian cells and many other organisms are well known to those skilled in the art.
- the full-length sequence of the nucleic acid molecule of the present invention or its fragments can usually be obtained by but not limited to PCR amplification method, recombination method or artificial synthesis method.
- the DNA sequence encoding the TCR (or a fragment or derivative thereof) of the present invention can be obtained completely through chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or such as vectors) and cells known in the art. DNA can be a coding strand or a non-coding strand.
- the present invention also relates to vectors containing the nucleic acid molecules of the present invention, including expression vectors, that is, constructs that can be expressed in vivo or in vitro.
- expression vectors include bacterial plasmids, bacteriophages, and animal and plant viruses.
- Virus delivery systems include, but are not limited to, adenovirus vectors, adeno-associated virus (AAV) vectors, herpes virus vectors, retrovirus vectors, lentivirus vectors, and baculovirus vectors.
- AAV adeno-associated virus
- the vector can transfer the nucleotide of the present invention into a cell, such as a T cell, so that the cell expresses a TCR specific for the AFP antigen.
- a cell such as a T cell
- the vector should be able to continuously express at a high level in T cells.
- the present invention also relates to a host cell produced by genetic engineering using the vector or coding sequence of the present invention.
- the host cell contains the vector of the present invention or the nucleic acid molecule of the present invention is integrated into the chromosome.
- the host cell is selected from: prokaryotic cells and eukaryotic cells, such as Escherichia coli, yeast cells, CHO cells and the like.
- the present invention also includes isolated cells expressing the TCR of the present invention, especially T cells.
- the T cells may be derived from T cells isolated from the subject, or may be a mixed cell population isolated from the subject, such as part of a peripheral blood lymphocyte (PBL) population.
- PBL peripheral blood lymphocyte
- the cells can be isolated from peripheral blood mononuclear cells (PBMC), and can be CD4 + helper T cells or CD8 + cytotoxic T cells.
- PBMC peripheral blood mononuclear cells
- the cells can be in a mixed population of CD4 + helper T cells/CD8 + cytotoxic T cells.
- the cells can be activated with antibodies (eg, anti-CD3 or anti-CD28 antibodies) so that they can be more easily transfected, for example, with a vector containing a nucleotide sequence encoding the TCR molecule of the present invention. dye.
- antibodies eg, anti-CD3 or anti-CD28 antibodies
- the cells of the present invention can also be or derived from stem cells, such as hematopoietic stem cells (HSC).
- stem cells such as hematopoietic stem cells (HSC).
- HSC hematopoietic stem cells
- T cell transfection with DNA or RNA encoding the TCR of the present invention There are many methods suitable for T cell transfection with DNA or RNA encoding the TCR of the present invention (eg, Robbins et al., (2008) J. Immunol. 180: 6116-6131). T cells expressing the TCR of the present invention can be used for adoptive immunotherapy. Those skilled in the art can know many suitable methods for adoptive therapy (eg, Rosenberg et al., (2008) Nat Rev Cancer 8(4):299-308).
- the present invention also relates to a method for treating and/or preventing AFP-related diseases in a subject, which includes the step of adoptively transferring AFP-specific T cells to the subject.
- the AFP-specific T cells can recognize the TSSELMAITR-HLA A1101 complex.
- the AFP-specific T cells of the present invention can be used to treat any AFP-related diseases that present the AFP antigen short peptide TSSELMAITR-HLA A1101 complex. Including but not limited to tumors, such as hepatocellular carcinoma.
- Treatment can be carried out by isolating T cells from patients or volunteers suffering from AFP antigen-related diseases, introducing the TCR of the present invention into the above-mentioned T cells, and then infusing these genetically engineered cells back into the patient's body for treatment. Therefore, the present invention provides a method for the treatment of AFP-related diseases, including the isolated T cell expressing the TCR of the present invention, preferably, the T cell is derived from the patient itself and transferred into the patient's body.
- the present invention includes (1) isolation of patient's T cells, (2) in vitro transduction of T cells with nucleic acid molecules of the present invention or nucleic acid molecules capable of encoding TCR molecules of the present invention, and (3) infusion of genetically engineered T cells into patients in vivo.
- the number of isolated, transfected, and reinfused cells can be determined by the physician.
- the TCR of the present invention can specifically bind to the AFP antigen short peptide complex TSSELMAITR-HLA A1101, and the cells transduced with the TCR of the present invention can be specifically activated.
- the synthetic short peptide TSSELMAITR (SEQ ID NO.: 9; Beijing Saibaisheng Gene Technology Co., Ltd.) was used to stimulate peripheral blood lymphocytes (PBL) from healthy volunteers with genotype HLA-A1101.
- the TSSELMAITR short peptide was renatured with biotin-labeled HLA-A1101 to prepare pHLA haploids. These haploids were combined with PE-labeled streptavidin (BD Company) to form a PE-labeled tetramer, and the tetramer and anti-CD8-APC double positive cells were sorted.
- the function and specificity of the T cell clone were further tested by ELISPOT experiment. Those skilled in the art are familiar with the method of using the ELISPOT assay to detect cell function.
- the effector cells used in the IFN- ⁇ ELISPOT experiment of this example are the T cell clones obtained in the present invention; and among the target cells, T2 cells (T2 cells transfected with HLA-A1101) and K562- cells are loaded with TSSELMAITR short peptide.
- AFP AFP overexpression
- T2 cells loaded with other short peptides T2 cells transfected with HLA-A1101) and K562 cells are negative target cells.
- ELISPOT plate First prepare the ELISPOT plate, and add the test components to the ELISPOT plate in the following order: 20,000 T2 cells/well, 2000 effector cells/well, add 20 ⁇ l of specific short peptides to the experimental group, and 20 ⁇ l non-specific short peptides to the control group , Add 20 ⁇ l culture medium (test culture medium) to the blank group, and set 2 replicate wells. Then incubate overnight (37°C, 5% CO 2 ). Then wash the plate and perform secondary detection and color development, dry the plate for 1 hour, and then use the immunospot plate reader
- T cell clones can be specifically activated by positive target cells; at the same time, the T cell clones basically did not respond to T2 cells and K562 loaded with other short peptides.
- the cDNA synthesis uses clontech’s SMART RACE cDNA amplification kit, and the primers used are designed in the C-terminal conserved region of the human TCR gene.
- the sequence was cloned into the T vector (TAKARA) for sequencing. It should be noted that this sequence is a complementary sequence and does not contain introns. After sequencing, the structure of the ⁇ chain and ⁇ chain sequence of the TCR expressed by the double-positive clone is shown in Figure 1 and Figure 2, respectively.
- Figure 1a, Figure 1b, Figure 1c, Figure 1d, Figure 1e and Figure 1f are the TCR ⁇ chain Variable domain amino acid sequence, TCR ⁇ chain variable domain nucleotide sequence, TCR ⁇ chain amino acid sequence, TCR ⁇ chain nucleotide sequence, TCR ⁇ chain amino acid sequence with leader sequence, and TCR ⁇ chain nucleotide sequence with leader sequence;
- Figure 2a, Figure 2b, Figure 2c, Figure 2d, Figure 2e and Figure 2f are the TCR ⁇ chain variable domain amino acid sequence, the TCR ⁇ chain variable domain nucleotide sequence, the TCR ⁇ chain amino acid sequence, the TCR ⁇ chain nucleotide sequence, and the leader sequence. TCR ⁇ chain amino acid sequence and TCR ⁇ chain nucleotide sequence with leader sequence.
- the ⁇ chain contains CDRs with the following amino acid sequence:
- the full-length genes of TCR alpha chain and beta chain were cloned into the lentiviral expression vector pLenti (addgene) by overlap PCR. Specifically: using overlap PCR to connect the full-length gene of the TCR ⁇ chain and the TCR ⁇ chain to obtain the TCR ⁇ -2A-TCR ⁇ fragment.
- the lentiviral expression vector and TCR ⁇ -2A-TCR ⁇ were digested and ligated to obtain the pLenti-TRA-2A-TRB-IRES-NGFR plasmid.
- a lentiviral vector pLenti-eGFP expressing eGFP was also constructed. Then use 293T/17 to package the fake virus.
- the ⁇ and ⁇ chains of the TCR molecule of the present invention may only contain the variable domain and part of the constant domain, respectively, and a cysteine residue is introduced into the constant domains of the ⁇ and ⁇ chains.
- the positions of introducing cysteine residues are Thr48 of TRAC*01 exon 1 and Ser57 of TRBC2*01 exon 1; the amino acid sequence and nucleotides of its ⁇ chain The sequence is shown in Figure 4a and Figure 4b, respectively, and the amino acid sequence and nucleotide sequence of the ⁇ chain are shown in Figure 5a and Figure 5b, respectively.
- the target gene sequences of the above-mentioned TCR ⁇ and ⁇ chains were synthesized and inserted into the expression vector pET28a+ (Novagene ), the upstream and downstream cloning sites are NcoI and NotI respectively. The inserted fragment was confirmed by sequencing.
- TCR ⁇ and ⁇ chains were transformed into expressing bacteria BL21(DE3) by chemical transformation method respectively.
- the ⁇ and ⁇ chains of TCR were expressed
- the inclusion bodies formed later were extracted by BugBuster Mix (Novagene) and washed repeatedly with BugBuster solution.
- the inclusion bodies were finally dissolved in 6M guanidine hydrochloride, 10mM dithiothreitol (DTT), 10mM ethylenediaminetetraacetic acid (EDTA) ), 20mM Tris (pH 8.1).
- the dissolved TCR ⁇ and ⁇ chains are quickly mixed in 5M urea, 0.4M arginine, 20mM Tris (pH 8.1), 3.7mM cystamine, 6.6mM ⁇ -mercapoethylamine (4°C) at a mass ratio of 1:1, and the final concentration is 60mg/mL.
- 5M urea 20mM Tris (pH 8.1)
- 20mM Tris 20mM Tris (pH 8.1)
- cystamine 3.7mM cystamine
- 6.6mM ⁇ -mercapoethylamine 4°C
- the solution is filtered through a 0.45 ⁇ M filter membrane and purified by an anion exchange column (HiTrap Q HP, 5ml, GE Healthcare).
- the elution peak contains the successfully renatured ⁇ and ⁇ dimer TCRs, which are confirmed by SDS-PAGE gel.
- the TCR is then further purified by gel filtration chromatography (HiPrep 16/60, Sephacryl S-100HR, GE Healthcare). The purity of the purified TCR was determined by SDS-PAGE to be greater than 90%, and the concentration was determined by the BCA method.
- the SDS-PAGE gel image of the soluble TCR obtained by the present invention is shown in FIG. 6.
- variable domains of the TCR alpha and beta chains in Example 2 were constructed into a stable soluble single-chain TCR molecule connected by a flexible short peptide (linker) by using the method of site-directed mutagenesis.
- the amino acid sequence and nucleotide sequence of the single-stranded TCR molecule are shown in Figure 7a and Figure 7b, respectively.
- the amino acid sequence and nucleotide sequence of the ⁇ chain variable domain are shown in Figure 8a and Figure 8b, respectively; the amino acid sequence and nucleotide sequence of the ⁇ chain variable domain are shown in Figure 9a and Figure 9b, respectively; its linker The amino acid sequence and nucleotide sequence of the sequence are shown in Figure 10a and Figure 10b, respectively.
- the target gene was digested with NcoI and NotI, and then connected to the pET28a vector that was digested with NcoI and NotI.
- the ligation product was transformed into E.coli DH5 ⁇ , spread on an LB plate containing kanamycin, incubated overnight at 37°C, and selected positive clones for PCR screening, and sequenced the positive recombinants to confirm the correct sequence and extract the recombinant plasmid for transformation To E.coli BL21(DE3), for expression.
- the inclusion bodies were dissolved in a buffer (20mM Tris-HCl pH 8.0, 8M urea), centrifuged at a high speed to remove insoluble materials, the supernatant was quantified by BCA method, then aliquoted, and stored at -80°C for later use.
- a syringe to drop the single-stranded TCR after the above treatment into 125mL of refolding buffer (100mM Tris-HCl pH 8.1, 0.4M L-arginine, 5M urea, 2mM EDTA, 6.5mM ⁇ -mercapthoethylamine, 1.87mM Cystamine), Stir at 4°C for 10 minutes, then put the refolding solution into a cellulose membrane dialysis bag with a cutoff of 4kDa, place the dialysis bag in 1L of pre-cooled water, and slowly stir overnight at 4°C.
- refolding buffer 100mM Tris-HCl pH 8.1, 0.4M L-arginine, 5M urea, 2mM EDTA, 6.5mM ⁇ -mercapthoethylamine, 1.87mM Cystamine
- the collected elution fractions were analyzed by SDS-PAGE, and the fractions containing single-stranded TCR were concentrated and further purified with a gel filtration column (Superdex 75 10/300, GE Healthcare), and the target fractions were also analyzed by SDS-PAGE.
- the eluted fractions used for BIAcore analysis were further tested for purity by gel filtration.
- the conditions are: Column Agilent Bio SEC-3 (300A, ), the mobile phase is 150mM phosphate buffer, the flow rate is 0.5mL/min, the column temperature is 25°C, and the UV detection wavelength is 214nm.
- the SDS-PAGE gel image of the soluble single-chain TCR obtained in the present invention is shown in FIG. 11.
- the BIAcore T200 real-time analysis system was used to detect the binding activity of the TCR molecules obtained in Example 3 and Example 5 with the TSSELMAITR-HLA A1101 complex.
- the unreacted activated surface was sealed with ethanolamine hydrochloric acid solution to complete the coupling process, and the coupling level was about 15,000 RU.
- the synthetic short peptide TSSELMAITR (Beijing Saibaisheng Gene Technology Co., Ltd.) was dissolved in DMSO to a concentration of 20 mg/ml.
- the inclusion bodies of the light chain and the heavy chain are dissolved with 8M urea, 20mM Tris pH 8.0, 10mM DTT, and 3M guanidine hydrochloride, 10mM sodium acetate, and 10mM EDTA are added before renaturation to further denature.
- TSSELMAITR peptide at 25mg/L (final concentration) to refolding buffer (0.4M L-arginine, 100mM Tris pH 8.3, 2mM EDTA, 0.5mM oxidized glutathione, 5mM reduced glutathione, 0.2mM PMSF, cooled to 4°C), then add 20mg/L light chain and 90mg/L heavy chain (final concentration, heavy chain is added three times, 8h/time), and renaturate at 4°C for at least 3 days Upon completion, SDS-PAGE will test whether the renaturation is successful.
- the protein-containing fractions were combined, concentrated with a Millipore ultrafiltration tube, the protein concentration was determined by the BCA method (Thermo), and the protease inhibitor cocktail (Roche) was added to store the biotinylated pMHC molecules in aliquots at -80°C.
- the soluble TCR molecules of the present invention and the kinetic profiles of the combination of the soluble single-chain TCR molecules constructed by the present invention and the TSSELMAITR-HLA A1101 complex are shown in Figure 12 and Figure 13, respectively.
- the map shows that both the soluble TCR molecules and soluble single-chain TCR molecules obtained in the present invention can bind to the TSSELMAITR-HLA A1101 complex.
- the above method was also used to detect the binding activity of the soluble TCR molecule of the present invention with several other unrelated antigen short peptides and HLA complexes. The results showed that the TCR molecule of the present invention did not bind to other unrelated antigens, which proved the solubleness of the present invention.
- TCR molecules can specifically bind to TSSELMAITR-HLA A1101 complex.
- ELISPOT assay to detect cell function. Construct a lentiviral vector containing the target gene of the TCR of the present invention, transduce the T cell, and perform an ELISPOT test to prove the specific activation response of the T cell transduced by the TCR of the present invention to the target cell.
- the IFN- ⁇ production detected by the ELISPOT test was used as the readout value of T cell activation.
- the target cells used in this experiment are T2 cells (T2 cells transfected with HLA-A1101) loaded with the AFP antigen short peptide TSSELMAITR, and the effector cells used are CD3 + T cells expressing the TCR of the present invention, and the same volunteers CD3 + T cells transfected with other TCR (A6) were used as a control group.
- the cells were expanded until 9-12 days after transduction, and then these cells were placed in the test medium and centrifuged at 300g for 10 minutes at room temperature for washing.
- the cells are then resuspended in the test medium at 2 ⁇ the desired final concentration.
- the negative control effector cells were treated in the same way.
- test components to the ELISPOT well plate: target cells 1 ⁇ 10 4 /well, effector cells 2 ⁇ 10 3 /well (calculated according to the antibody positive rate), and set up two duplicate wells. The plate was then incubated overnight (37°C/5% CO 2 ).
- the detection antibody was diluted 1:200 with PBS containing 10% FBS, and 100 ⁇ l/well was added to each well. Incubate the well plate for 2 hours at room temperature, and then wash it 3 times with washing buffer. Tap the well on a paper towel to remove excess washing buffer. Dilute streptavidin-alkaline phosphatase 1:100 with PBS containing 10% FBS, add 100 microliters of diluted streptavidin-alkaline phosphatase to each well and incubate the plate at room temperature 1 hour.
- the results of the experiment are shown in Figure 15.
- the T cells transduced with the TCR of the present invention have an obvious activation response when the concentration of the antigen short peptide is low, while the T cells transduced with other TCRs There is still no activation state at higher concentrations of antigen short peptides.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
Abstract
Description
Claims (26)
- 一种T细胞受体(TCR),其特征在于,所述TCR能够与TSSELMAITR-HLA A1101复合物结合;并且,所述TCR包含TCRα链可变域和TCRβ链可变域,所述TCRα链可变域的3个互补决定区(CDR)为:αCDR1-YGATPY (SEQ ID NO:10)αCDR2-YFSGDTLV (SEQ ID NO:11)αCDR3-AVVATDSWGKLQ (SEQ ID NO:12);和/或所述TCRβ链可变域的3个互补决定区为:βCDR1-SGHVS (SEQ ID NO:13)βCDR2-FQNEAQ (SEQ ID NO:14)βCDR3-ASSLVAGARTDTQY (SEQ ID NO:15)。
- 如权利要求1所述的TCR,其特征在于,其包含TCRα链可变域和TCRβ链可变域,所述TCRα链可变域为与SEQ ID NO:1具有至少90%序列相同性的氨基酸序列;和/或所述TCRβ链可变域为与SEQ ID NO:5具有至少90%序列相同性的氨基酸序列。
- 如权利要求1所述的TCR,其特征在于,所述TCR包含α链可变域氨基酸序列SEQ ID NO:1;和/或所述TCR包含β链可变域氨基酸序列SEQ ID NO:5。
- 如权利要求1所述的TCR,其特征在于,所述TCR为αβ异质二聚体,其包含TCRα链恒定区TRAC*01和TCRβ链恒定区TRBC1*01或TRBC2*01;优选地,所述TCR的α链氨基酸序列为SEQ ID NO:3和所述TCR的β链氨基酸序列为SEQ ID NO:7。
- 如权利要求1所述的TCR,其特征在于,所述TCR是可溶的。
- 如权利要求5所述的TCR,其特征在于,所述TCR为单链;优选地,所述TCR是由α链可变域与β链可变域通过肽连接序列连接而成。
- 如权利要求6所述的TCR,其特征在于,所述TCR在α链可变区氨基酸第11、13、19、21、53、76、89、91、或第94位,和/或α链J基因短肽氨基酸倒数第3位、倒数第5位或倒数第7位中具有一个或多个突变;和/或所述TCR在β链可变区氨基酸第11、13、19、21、53、76、89、91、或第94位,和/或β链J基因短肽氨基酸倒数第2位、倒数第4位或倒数第6位中具有一个或多个突变,其中氨基酸位置编号按IMGT(国际免疫遗传学信息系统)中列出的位置编号;优选地,所述TCR的α链可变域氨基酸序列包含SEQ ID NO:32和/或所述TCR的β链可变域氨基酸序列包含SEQ ID NO:34;更优选地,所述TCR的氨基酸序列为SEQ ID NO:30。
- 如权利要求1所述的TCR,其特征在于,所述TCR包含(i)TCRα链可变域和除跨膜结构域以外的全部或部分TCRα链恒定区;和(ii)TCRβ链可变域和除跨膜结构域以外的全部或部分TCRβ链恒定区。
- 如权利要求8所述的TCR,其特征在于,半胱氨酸残基在所述TCR的α和β链恒定域之间形成人工二硫键;优选地,在所述TCR中形成人工二硫键的半胱氨酸残基取代了 选自下列的一组或多组位点:TRAC*01外显子1的Thr48和TRBC1*01或TRBC2*01外显子1的Ser57;TRAC*01外显子1的Thr45和TRBC1*01或TRBC2*01外显子1的Ser77;TRAC*01外显子1的Tyr10和TRBC1*01或TRBC2*01外显子1的Ser17;TRAC*01外显子1的Thr45和TRBC1*01或TRBC2*01外显子1的Asp59;TRAC*01外显子1的Ser15和TRBC1*01或TRBC2*01外显子1的Glu15;TRAC*01外显子1的Arg53和TRBC1*01或TRBC2*01外显子1的Ser54;TRAC*01外显子1的Pro89和TRBC1*01或TRBC2*01外显子1的Ala19;和TRAC*01外显子1的Tyr10和TRBC1*01或TRBC2*01外显子1的Glu20。
- 如权利要求9所述的TCR,其特征在于,所述TCR的α链氨基酸序列为SEQ ID NO:26和/或所述TCR的β链氨基酸序列为SEQ ID NO:28。
- 如权利要求8所述的TCR,其特征在于,所述TCR的α链可变区与β链恒定区之间含有人工链间二硫键;优选地,在所述TCR中形成人工链间二硫键的半胱氨酸残基取代了选自下列的一组或多组位点:TRAV的第46位氨基酸和TRBC1*01或TRBC2*01外显子1的第60位氨基酸;TRAV的第47位氨基酸和TRBC1*01或TRBC2*01外显子1的61位氨基酸;TRAV的第46位氨基酸和TRBC1*01或TRBC2*01外显子1的第61位氨基酸;或TRAV的第47位氨基酸和TRBC1*01或TRBC2*01外显子1的第60位氨基酸。
- 如权利要求1所述的TCR,其特征在于,所述TCR包含α链恒定区和β链恒定区,所述α链恒定区为鼠源的和/或所述β链恒定区为鼠源的。
- 如权利要求1所述的TCR,其特征在于,所述TCR的α链和/或β链的C-或N-末端结合有偶联物;优选地,与所述T细胞受体结合的偶联物为可检测标记物或治疗剂;更优选地,所述治疗剂为抗-CD3抗体。
- 如权利要求1所述的TCR,其特征在于,所述TCR是分离的或纯化的。
- 一种多价TCR复合物,其特征在于,包含至少两个TCR分子,并且其中的至少一个TCR分子为上述权利要求中任一项所述的TCR。
- 一种核酸分子,其特征在于,所述核酸分子包含编码上述任一权利要求所述的TCR分子的核酸序列或其互补序列。
- 如权利要求16所述的核酸分子,其特征在于,其包含编码TCRα链可变域的核苷酸序列SEQ ID NO:2或SEQ ID NO:33。
- 如权利要求16或17所述的核酸分子,其特征在于,其包含编码TCRβ链可变域的核苷酸序列SEQ ID NO:6或SEQ ID NO:35。
- 如权利要求16所述的核酸分子,其特征在于,其包含编码TCRα链的核苷酸序列SEQ ID NO:4和/或包含编码TCRβ链的核苷酸序列SEQ ID NO:8。
- 一种载体,其特征在于,所述的载体含有权利要求16-19中任一所述的核酸分子;优选地,所述的载体为病毒载体;更优选地,所述的载体为慢病毒载体。
- 一种分离的宿主细胞,其特征在于,所述的宿主细胞中含有权利要求20中所述的载体或染色体中整合有外源的权利要求16-19中任一所述的核酸分子。
- 一种细胞,其特征在于,所述细胞中转导有权利要求16-19中任一所述的核酸分子或权利要求20中所述载体;优选地,所述细胞为T细胞或干细胞。
- 一种药物组合物,其特征在于,所述组合物含有药学上可接受的载体以及权利要求1-14中任一项所述的TCR、权利要求15中所述的TCR复合物、或权利要求22中所述的细胞。
- 权利要求1-14中任一项所述的T细胞受体、或权利要求15中所述的TCR复合物或权利要求22中所述的细胞的用途,其特征在于,用于制备治疗肿瘤或自身免疫疾病的药物;优选地,所述肿瘤为肝癌。
- 权利要求1-14中任一项所述的T细胞受体、或权利要求15中所述的TCR复合物或权利要求22中所述的细胞,用作治疗肿瘤或自身免疫疾病的药物;优选地,所述肿瘤为肝癌。
- 一种治疗疾病的方法,其特征在于,包括给需要治疗的对象施用适量的权利要求1-14中任一所述的TCR、权利要求15中所述TCR复合物、权利要求22中所述的细胞或权利要求23中所述的药物组合物;优选地,所述的疾病为肿瘤,更优选地所述肿瘤为肝癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010130645.2A CN113321727B (zh) | 2020-02-28 | 2020-02-28 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
CN202010130645.2 | 2020-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021170117A1 true WO2021170117A1 (zh) | 2021-09-02 |
Family
ID=77412833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/078277 WO2021170117A1 (zh) | 2020-02-28 | 2021-02-26 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN113321727B (zh) |
TW (1) | TW202140539A (zh) |
WO (1) | WO2021170117A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898399A (zh) * | 2019-12-03 | 2021-06-04 | 香雪生命科学技术(广东)有限公司 | 源自于afp抗原的短肽 |
CN113321727A (zh) * | 2020-02-28 | 2021-08-31 | 香雪生命科学技术(广东)有限公司 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104087592A (zh) * | 2014-05-13 | 2014-10-08 | 天津医科大学总医院 | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 |
WO2015011450A1 (en) * | 2013-07-26 | 2015-01-29 | Adaptimmune Limited | T cell receptors |
CN110776562A (zh) * | 2018-07-30 | 2020-02-11 | 广东香雪精准医疗技术有限公司 | 一种识别afp抗原的t细胞受体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019036688A1 (en) * | 2017-08-18 | 2019-02-21 | Gritstone Oncology, Inc. | ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS |
CN110343166B (zh) * | 2018-04-03 | 2022-10-28 | 香雪生命科学技术(广东)有限公司 | 识别afp抗原短肽的t细胞受体 |
CN110577591B (zh) * | 2018-06-08 | 2022-10-28 | 香雪生命科学技术(广东)有限公司 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
CN113321727B (zh) * | 2020-02-28 | 2024-04-09 | 香雪生命科学技术(广东)有限公司 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
CN113667008A (zh) * | 2020-05-15 | 2021-11-19 | 香雪生命科学技术(广东)有限公司 | 一种识别afp抗原的高亲和力t细胞受体 |
-
2020
- 2020-02-28 CN CN202010130645.2A patent/CN113321727B/zh active Active
-
2021
- 2021-02-26 TW TW110107140A patent/TW202140539A/zh unknown
- 2021-02-26 WO PCT/CN2021/078277 patent/WO2021170117A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015011450A1 (en) * | 2013-07-26 | 2015-01-29 | Adaptimmune Limited | T cell receptors |
CN104087592A (zh) * | 2014-05-13 | 2014-10-08 | 天津医科大学总医院 | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 |
CN110776562A (zh) * | 2018-07-30 | 2020-02-11 | 广东香雪精准医疗技术有限公司 | 一种识别afp抗原的t细胞受体 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112898399A (zh) * | 2019-12-03 | 2021-06-04 | 香雪生命科学技术(广东)有限公司 | 源自于afp抗原的短肽 |
CN113321727A (zh) * | 2020-02-28 | 2021-08-31 | 香雪生命科学技术(广东)有限公司 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
CN113321727B (zh) * | 2020-02-28 | 2024-04-09 | 香雪生命科学技术(广东)有限公司 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
Also Published As
Publication number | Publication date |
---|---|
CN113321727A (zh) | 2021-08-31 |
TW202140539A (zh) | 2021-11-01 |
CN113321727B (zh) | 2024-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7452880B2 (ja) | Ssx2抗原を識別するt細胞受容体 | |
WO2021068938A1 (zh) | 一种识别kras突变的t细胞受体及其编码序列 | |
WO2017076308A1 (zh) | 识别ny-eso-1抗原短肽的tcr | |
CN106749620B (zh) | 识别mage-a1抗原短肽的t细胞受体 | |
CN110343166B (zh) | 识别afp抗原短肽的t细胞受体 | |
WO2020024915A1 (zh) | 一种识别afp抗原的t细胞受体 | |
WO2021170115A1 (zh) | 一种识别hpv的t细胞受体 | |
CN109575121B (zh) | 识别afp抗原短肽的t细胞受体 | |
CN110577591B (zh) | 一种识别afp抗原短肽的t细胞受体及其编码序列 | |
WO2021139698A1 (zh) | 一种识别hpv抗原的t细胞受体及其编码序列 | |
WO2021022447A1 (zh) | 识别afp抗原短肽的t细胞受体 | |
WO2021016887A1 (zh) | 识别ssx2抗原短肽的t细胞受体 | |
WO2021170117A1 (zh) | 一种识别afp抗原短肽的t细胞受体及其编码序列 | |
WO2021170116A1 (zh) | 一种识别afp的t细胞受体 | |
WO2021139699A1 (zh) | 一种识别afp的t细胞受体及其编码序列 | |
CN110627894B (zh) | 识别ny-eso-1抗原短肽的t细胞受体及其编码序列 | |
CN110577590B (zh) | 一种识别afp抗原的tcr及其编码核酸 | |
CN110407927B (zh) | 一种识别afp抗原的tcr | |
WO2022262835A1 (zh) | 一种识别afp抗原的tcr及其编码序列 | |
WO2021035446A1 (zh) | 一种识别afp抗原短肽的t细胞受体及其编码序列 | |
WO2022206861A1 (zh) | 识别afp的t细胞受体 | |
WO2022166904A1 (zh) | 一种识别hpv的t细胞受体 | |
CN110272483B (zh) | 识别sage1抗原短肽的t细胞受体 | |
CN110407926B (zh) | 一种识别lmp1抗原短肽的tcr及其编码序列 | |
CN116135878A (zh) | 一种识别afp抗原的tcr |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21760886 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21760886 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21.02.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21760886 Country of ref document: EP Kind code of ref document: A1 |